CSIMarket
 
Ultragenyx Pharmaceutical Inc   (RARE)
 

News




Ultragenyx*s Strategic Move: Unlocking Employee Potential and Driving Company Growth through Restricted Stock Units)

UX111: Advancements in Reducing Heparan Sulfate Exposure for Improved Cognitive Function in Sanfilippo Syndrome Type A

Unveiling the Promising Frontier in Wilson Disease Therapy: UX701 Gene Therapy Raises Hope for Novel Treatment Approaches

Ultragenyx Pharmaceutical Grants Restricted Stock Units to Newly Hired Officers, Demonstrating Commitment to Employee Retention

Ultragenyx*s Evkeeza receives NICE Recommendation as Breakthrough Treatment for Homozygous Familial Hypercholesterolemia in the UK

Charting New Therapeutic Pathways: Insights from Ultragenyx?s Phase 1/2 Trial of GTX-102 in Pediatric Angelman Syndrome Patients.

Ultragenyx Pharmaceuticals Invests in Top Talent with Inducement Grants, Strengthening their Rare Disease Research and Development Portfolio

Ultragenyx Pharmaceutical Inc. Boosts Employee Engagement and Retention Through Inducement Grant of Restricted Stock Units

Ultragenyx Pharmaceutical Inc Surges Ahead with Impressive Revenue Growth in Q3 2023

The Major Pharmaceutical Preparations company declared surge in revenue, during the April to June 30 2023 interval

Despite Revenue Boost, Ultragenyx Pharmaceutical Inc Falls Short of Profitability in First Quarter of 2023

Ultragenyx Pharmaceutical Inc declared 23.935%, Revenues Increase, in the fourth quarter of 2022

The Major Pharmaceutical Preparations company has failed to break-even in the wake of epic Surge in revenue the Ultragenyx Pharmaceutical Inc all along the fourth quarter of 2017 earnings season









Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com